-
1
-
2
Outcomes distribution of drug patients with the top 50 positive signal frequency by 4 methods (ROR PRR IC MGPS).
Опубліковано 2025Предмети: -
3
-
4
-
5
Top 50 drugs sorted by frequency of positive signals stratified by reporter – by 4 methods (ROR PRR IC MGPS).
Опубліковано 2025Предмети: -
6
Gender Difference analysis of the top 50 drugs ranked by frequency by four methods (ROR PRR IC MGPS).
Опубліковано 2025Предмети: -
7
Top 50 Drugs with positive signals by frequency – by four methods (ROR PRR IC MGPS).
Опубліковано 2025Предмети: -
8
-
9
The top 50 drugs by frequency of positive signals stratified by sex – by 4 methods (ROR PRR IC MGPS).
Опубліковано 2025Предмети: -
10
-
11
The top 25 drugs sorted by frequency of positive signals stratified by age – by 4 methods (ROR PRR IC MGPS).
Опубліковано 2025Предмети: -
12
The principles of disproportionate measurement and the criteria for signal detection.
Опубліковано 2025Предмети: -
13
APP deficiency did not affect the mRNA level of <i>Scn8a</i> in cerebellar PCs.
Опубліковано 2025Предмети: -
14
-
15
L7 promoter-driven Cre recombinase expression is restricted to PCs in the cerebellar cortex.
Опубліковано 2025Предмети: -
16
Nav1.6 mediated the deficits of PC firing and motor function in APP-null mice.
Опубліковано 2025Предмети: -
17
-
18
-
19
Antibody validation for Nav1.6 and Nav1.1-EGFP in transfected HEK293 cells.
Опубліковано 2025Предмети: -
20